Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer
- 18 October 2002
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 9 (11) , 935-945
- https://doi.org/10.1038/sj.cgt.7700510
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Therapy, 2000
- Local and Systemic Therapy of Human Prostate Adenocarcinoma with the Conditionally Replicating Herpes Simplex Virus Vector G207Human Gene Therapy, 1999
- Therapeutic Efficiency and Safety of a Second-Generation Replication-Conditional HSV1 Vector for Brain Tumor Gene TherapyHuman Gene Therapy, 1997
- A Novel Multiply-Mutated HSV-1 Strain for the Treatment of Human Brain TumorsHuman Gene Therapy, 1997
- Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomasNature Medicine, 1995
- Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.Proceedings of the National Academy of Sciences, 1995
- Selective Destruction of Gliomas in Immunocompetent Rats by Thymidine Kinase-Defective Herpes Simplex Virus Type 1JNCI Journal of the National Cancer Institute, 1994
- Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus MutantScience, 1991
- Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutantVirology, 1988
- Reduction of RibonucleotidesAnnual Review of Biochemistry, 1979